BofA warns Fed risks policy mistake with early rate cuts
Investing.com - Argus Research initiated coverage on DexCom (NASDAQ:DXCM) with a Buy rating and set a price target of $100.00 on Thursday. This aligns with the broader market sentiment, as InvestingPro data shows a strong analyst consensus recommendation of 1.42 (Strong Buy), with price targets ranging from $83 to $115.
The research firm cited DexCom’s position as a designer, manufacturer, and marketer of continuous glucose monitoring (CGM) systems for people with diabetes as a key factor in its positive outlook.
DexCom generated 72% of its 2024 revenues from the U.S. market, with the remaining 28% coming from international operations, according to Argus.
The company maintains significant manufacturing facilities in the United States and Malaysia, with a new facility in Ireland that Argus views favorably for limiting tariff exposure.
Continuous glucose monitoring systems help diabetes patients maintain glycemic control and reduce diabetes-related health complications, positioning DexCom in an important healthcare technology segment.
In other recent news, DexCom reported impressive financial results for the second quarter of 2025, surpassing both earnings and revenue expectations. The company’s earnings per share were $0.48, exceeding the projected $0.45, while revenue reached $1.16 billion, above the anticipated $1.12 billion. These results highlight a strong performance, with the company achieving a 2.8% and 7.9% beat on top and bottom-line estimates, respectively. In response to these positive financials, UBS adjusted its price target for DexCom to $106 from $105, maintaining a Buy rating on the stock. This adjustment reflects confidence in the company’s continued growth prospects. Despite the strong fundamentals, the stock experienced a decline in after-market trading. However, UBS’s revised price target suggests optimism about DexCom’s future performance. These developments are part of the latest updates concerning the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.